BiotechTube
Madorra

Madorra

Palo Alto, United States· Est.
madorra.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.8M

Overview

Madorra is a private, pre-revenue medical device company founded in 2014 and headquartered in Portland, Oregon. The company is developing a novel, nonhormonal device for the treatment of moderate to severe vulvovaginal atrophy (vaginal dryness), a condition prevalent in post-menopausal women and breast cancer survivors. It has received Breakthrough Device Designation from the FDA for its technology, indicating significant potential to address an unmet need. Madorra is led by an experienced team with backgrounds in medical devices and women's health, and is backed by notable venture capital firms.

Women's HealthMenopauseOncology Supportive Care

Technology Platform

Nonhormonal, noninvasive medical device for treating vulvovaginal atrophy (vaginal dryness).

Funding History

2
Total raised:$2.8M
Series A$2.3M
Seed$500K

Opportunities

The large, underserved market of post-menopausal women and breast cancer survivors suffering from vaginal dryness presents a significant opportunity.
FDA Breakthrough Device Designation accelerates regulatory pathways and validates the unmet need.
A successful nonhormonal device could become a standard of care for patients contraindicated for or averse to estrogen therapy.

Risk Factors

The company faces clinical and regulatory risk in achieving FDA approval.
Post-approval, it must build commercial infrastructure and secure reimbursement in a competitive market.
Market adoption may be slow due to patient and physician familiarity with existing, simpler options.

Competitive Landscape

Competition includes over-the-counter lubricants/moisturizers, prescription vaginal estrogens (creams, rings, tablets), and emerging systemic nonhormonal drugs. Madorra's device aims to compete by offering a nonhormonal, potentially more effective and longer-lasting treatment compared to OTC products, while avoiding the risks and stigma associated with hormonal therapies.

More companies in Drug Delivery & Formulation →More companies in United States →